MedTrace Logo

Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies

NCT07415837 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-02-25

No results posted yet for this study

Summary

The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.

MicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.

The main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:

1. Patients with Duchenne or Becker muscular dystrophy (DMD/DMB).
2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease).
3. Patients with congenital myopathies.
4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.

Conditions

  • Duchenne / Becker Muscular Dystrophy
  • Dystrophia Myotonica 1
  • Congenital Myopathies
  • Healthy Participants

Interventions

DIAGNOSTIC_TEST

dosage of blood biomarker miR1

Patients and controls will be asked to provide blood samples to evaluate their blood level of miR1 biomarker on a unique time participation.

Sponsors & Collaborators

  • iGreD, Université Clermont Auvergne

    collaborator UNKNOWN

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Catherine Sarret, MD, PhD, Prof · CHU de Clermont-Ferrand

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-11
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07415837 on ClinicalTrials.gov